LEQEMBI And LENVIMA Will Strengthen Market Position Despite Regulatory And Competitive Challenges

AN
AnalystConsensusTarget
Consensus Narrative from 13 Analysts
Published
25 Nov 24
Updated
31 Jul 25
AnalystConsensusTarget's Fair Value
JP¥4,461.54
3.5% undervalued intrinsic discount
31 Jul
JP¥4,304.00
Loading
1Y
-18.0%
7D
1.2%

Author's Valuation

JP¥4.5k

3.5% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on01 May 25
Fair value Decreased 10%

Shared on23 Apr 25
Fair value Decreased 3.05%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on17 Apr 25
Fair value Decreased 0.69%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on09 Apr 25
Fair value Increased 0.30%

AnalystConsensusTarget has increased revenue growth from 2.3% to 2.6%.

Shared on02 Apr 25
Fair value Increased 15%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on26 Mar 25
Fair value Decreased 16%

Shared on19 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on12 Mar 25
Fair value Increased 19%

AnalystConsensusTarget has decreased revenue growth from 5.4% to 3.4%.